Andrea Gonzales , PhD
1355 Bogue St Room B346
Biography
Thirty years of delivering innovative, life-saving therapeutics to people and animals. Roles in the pharmaceutical industry have included Vice President of Global Companion Animal Therapeutics at Zoetis and leadership positions in areas such as Allergy and Dermatology, Inflammation, Oncology, Toxicology, and Pharmacology in both Animal Health and Human Health Divisions at companies including the Upjohn Co, Parke-Davis, Pfizer, and Zoetis. Contributions to numerous drug approvals include: • Apoquel®/Apoquel® Chewable, (oclacitinib maleate) a selective Janus Kinase 1 inhibitor approved for the treatment of dogs with allergic or atopic dermatitis • Cytopoint®, a canine anti-IL-31 monoclonal antibody (mAb) approved for the treatment of allergic or atopic dermatitis in dogs • Solensia®, a feline anti-NGF mAb approved for the treatment of cats with osteoarthritis pain • Librela®, a canine anti-NGF- mAb approved for the treatment of canine pain associated with osteoarthritis • Vizimpro® (dacomitinib) an irreversible pan-erbB inhibitor for the first-line treatment of human patients with EGFR-mutated metastatic non-small cell lung cancer • Ibrance® (palbociclib) a CDK4/6 inhibitor used to treat HR+, HER2- breast cancer • Rescriptor® (delavirdine mesylate) a non-nucleoside reverse transcriptase inhibitor (NNRTI) of Human Immunodeficiency Virus 1 (HIV-1)
Education
PhD in Toxicology, Curriculum in Toxicology, University of North Carolina at Chapel Hill, 1992
BS in Biology with Distinction, Literature, Sciences and Arts, University of Michigan, 1986
Employment
Professor and Director of Drug Discovery, Michigan State University, East Lansing, 2025 - Present
Publications
Effect of Gabapentin Administered With Prednisolone, Ciclosporin or a Placebo on Clinical Outcomes and Motor Activity in Cats With Atopic Skin Syndrome: A Prospective, Blinded, Placebo-Controlled Study. Veterinary dermatology (2025)
Oclacitinib (APOQUEL®) is a selective Janus kinase 1 inhibitor with efficacy in a canine model of flea allergic dermatitis Journal of Veterinary Pharmacology and Therapeutics (2024)
Comparison of intradermal and serum testing for environmental allergen‐specific immunoglobulin E determination in a laboratory colony of cats with naturally acquired atopic syndrome Veterinary Dermatology (2024)
Comparison of intradermal and serum testing for environmental allergen-specific immunoglobulin E determination in a laboratory colony of cats with naturally acquired atopic syndrome. Veterinary dermatology (2024)
Cytokine transcriptome profiling in acute experimental canine atopic dermatitis skin lesions after IL‐31 inhibition with lokivetmab Veterinary Dermatology (2023)
Cytokine transcriptome profiling in acute experimental canine atopic dermatitis skin lesions after IL-31 inhibition with lokivetmab. Veterinary dermatology (2023)
Oclacitinib 10 years later: lessons learned and directions for the future. Journal of the American Veterinary Medical Association (2023)
Laboratory safety evaluation of lokivetmab, a canine anti-interleukin-31 monoclonal antibody, in dogs. Veterinary immunology and immunopathology (2023)
Lack of Interference of Oclacitinib with the results of intradermal testing or allergen-specific IgE serology in Dermatophagoides farinae-sensitized beagle dogs. Veterinary immunology and immunopathology (2022)
Speed of onset of a new chewable formulation of oclacitinib maleate (Apoquel®) in a canine model of IL‐31‐induced pruritus Journal of Veterinary Pharmacology and Therapeutics (2022)
Speed of onset of a new chewable formulation of oclacitinib maleate (Apoquel®) in a canine model of IL-31-induced pruritus. Journal of veterinary pharmacology and therapeutics (2022)